Onda 8mg/4mg Solution For Injection Ampoule (Ondansetron)
Onda 4mg is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of postoperative nausea and vomiting (PONV).
In the pediatric population, Onda 4mg is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged ?6 months, and for the prevention and treatment of PONV in children aged 1 month.
Share Now
Additional Information
| Name | Onda |
| Description | Ondansetron is a potent and highly selective 5HT3 – receptors antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine by activating the vagal afferents via 5HT3 – receptors. Ondansetron blocks the initiation of this reflex. |
| Active Ingredient | Ondansetron |
| Indication | Onda is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of postoperative nausea and vomiting (PONV). In the pediatric population, Onda is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged 6 months, and for the prevention and treatment of PONV in children aged 1 month. |
| Strengths | ONDA solution for injection 4 mg/2 ml ONDA solution for injection 8 mg/4 ml Ondansetron Film coated tablets 8 mg |
| Regulatory Status | Registered |
| Business Partner | VIANEX S.A- PLANT A |
| Origin | Athens-Greece |
Related Products
Disclaimer
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.
